|
1 2 3 4 5 6 7
далее ian cancer, fallopian tube carcinoma, and peritoneal carcinoma/ DeVita V.T, Hellman S. Cancer: principles and practice of oncology.6th. 2001: p. 1597-632. 4. Ozols R.F. Update on the management of ovarian cancer. Cancer J 2002: 2( Suppl. 1 ):S22-30. 5. Colombo N. Controversies in chemotherapy- what is standard treatment? European Journal of Cancer2003.Vol1 N6, 107-114 6. Boggs W. Topotecan effective in Recurrent Ovarian cancer, J Clin, Oncol.2000,18. 7. Garcia-Garbonero R. Jeffrey G. Et all. Current Perspectives on the Clinical Experience, Pharmacology, and Continued development of the Camptothecins. Minireview. Clinical Cancer research. V 6, 641-661, 2002 8. ten Bokkel Huinink W, Gore M et al. Topotecan versus Paclitaxel for the treatment of recurrent epithelian ovarian cancer. J.CIin. Oncol. 1997: 15:2183-2193 9. Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999; 4 (2):87-94. 10. McGuire W, Blessing J, Bookman M, et all. Topotecan has substantial antitumor activity as first line salvage therapy in platinum-sensitive epithelian ovarian carcinoma. J Clin. Oncol 2002: 18 (5):1-7. 11. Bookman M.A et all. Extending the Platinum- Free Interval in Recurrent Ovarian cancer: the role of Topotecan in Second -Line Chemotherapy. The Oncologist 1999: 4: 87-94). 12. Gordon A.N, fleagle J.t et all. Recurrrent epithelian ovarian carcinoma: a randomized phase 3 study of pegylated liposomal doxorubicin ersus topotecan. J.CIin. Oncol. 2001; 19:3312-22 13. Prasad M. Ben-Porat L. et all. Cost of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynrcologic Oncology 93 ( 2004) 223-228. 14. Vermorker J., Gore m. et all. Multicenter Randomized phase 2 study of Oxaliplatin or Topotecan in Platinum-Pretreated epithelial Ovarian cancer. Proc.ASCO 2001:20;847a. 15. Slomovitz B.M. Coleman R.L. et all. Phase 1 study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. ASCO 2006, abst.5090. 16. Parmar M.K. Ledermann J.A. et all. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer, the ICON4\ AGO- OVAR-2.2 trial, lancet 2003: 361: 2099-2106. 17. Ledermann J.A: Randomised trial of Paclitaxel in combination with platinum chemotherapy v.s platinum-based chemotherapy in the treatment of relapsed ovarian cancer) ICON 4/OVAR2.2) On behalf of ICON and AGO Collaborators, 2003 18. Stanley B.Koye H.D Chemoterapy for Ovarian Cancer Futur Potential for new and Existing Drugs. ASCO 2005, 411-415 19. Gronlund В. Engelholm S. et all. Secuential Topotecan and Oral Etoposide in recurrent ovarian carcinoma pretreated with platinumi taxane. Cancer.2005:103 (7):)388-93, 20. Sehouli J. Sommer H. et all. A randomized multicenter phase 3 trialof topotecan monotherapy versus topotecan далее ...
|
